[{"id":"c84b4894-7b72-40e5-b7d9-73619eecd885","acronym":"22P.205","url":"https://clinicaltrials.gov/study/NCT05564650","created_at":"2022-10-03T15:56:48.447Z","updated_at":"2025-02-25T15:35:52.261Z","phase":"Phase 1/2","brief_title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05564650 - 22P.205","lead_sponsor":"Thomas Jefferson University","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 04/10/2026","primary_completion_date":" 04/10/2026","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2025-02-11"},{"id":"5a8a1ba9-7750-4d42-886f-26c4d198762e","acronym":"NCI-2018-01812","url":"https://clinicaltrials.gov/study/NCT03672539","created_at":"2021-01-18T18:00:52.647Z","updated_at":"2025-02-25T15:43:12.491Z","phase":"Phase 2","brief_title":"Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03672539 - NCI-2018-01812","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-10"},{"id":"9436a8ff-5aa6-4f94-a70c-ecf2cecaa874","acronym":"NCI-2022-02215","url":"https://clinicaltrials.gov/study/NCT05285813","created_at":"2023-08-14T10:11:07.915Z","updated_at":"2024-07-02T16:34:58.922Z","phase":"Phase 2","brief_title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","source_id_and_acronym":"NCT05285813 - NCI-2022-02215","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vibecotamab (XmAb14045)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"},{"id":"619771d1-d4a0-44c2-8ac6-1aa798882b7f","acronym":"TAGALONG","url":"https://clinicaltrials.gov/study/NCT05442216","created_at":"2023-08-14T10:11:09.139Z","updated_at":"2024-07-02T16:35:06.443Z","phase":"Phase 2","brief_title":"Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents","source_id_and_acronym":"NCT05442216 - TAGALONG","lead_sponsor":"Joshua Zeidner","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-02"},{"id":"76d3be7f-1ce4-4404-98c7-4c495cf2ba18","acronym":"","url":"https://clinicaltrials.gov/study/NCT03816319","created_at":"2021-01-29T07:18:38.008Z","updated_at":"2024-07-02T16:35:08.645Z","phase":"Phase 1","brief_title":"TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03816319","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAK-243"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 08/30/2024","start_date":" 08/30/2024","primary_txt":" Primary completion: 12/11/2024","primary_completion_date":" 12/11/2024","study_txt":" Completion: 12/11/2024","study_completion_date":" 12/11/2024","last_update_posted":"2024-04-19"},{"id":"80bbead0-defc-4564-bc2a-476e047424b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02936752","created_at":"2021-01-29T07:13:34.466Z","updated_at":"2024-07-02T16:35:13.077Z","phase":"Phase 1","brief_title":"Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents","source_id_and_acronym":"NCT02936752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/23/2017","start_date":" 06/23/2017","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 03/21/2025","study_completion_date":" 03/21/2025","last_update_posted":"2024-03-25"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"8b2804e8-60bc-4a10-b758-708f1c1c2065","acronym":"GFM-CPX MDS","url":"https://clinicaltrials.gov/study/NCT04273802","created_at":"2021-01-18T20:45:32.651Z","updated_at":"2024-07-02T16:36:07.662Z","phase":"Phase 1/2","brief_title":"CPX-351 in Higher Risk Myelodysplastic Syndromes","source_id_and_acronym":"NCT04273802 - GFM-CPX MDS","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/29/2020","start_date":" 04/29/2020","primary_txt":" Primary completion: 08/27/2021","primary_completion_date":" 08/27/2021","study_txt":" Completion: 07/06/2022","study_completion_date":" 07/06/2022","last_update_posted":"2022-07-07"}]